ClinicalTrialsFinder

Post-ET Myelofibrosis Clinical Trials in Seattle, Washington

1 recruitingSeattle, Washington

Showing 1–1 of 1 trials

Recruiting
Phase 3

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135